NCT Number: NCT03781284
PET Combined With MRI for Monitoring Inflammatory Activity in Patients With Ulcerative Colitis
Colonoscopy is considered crucial for the diagnosis and quantification of ulcerative colitis (UC). However, there are several drawbacks related to the invasiveness, procedure-related discomfort, risk of bowel perforation (especially in the period of acute inflammation), and relatively poor patient acceptance. Most patients regard the necessary bowel cleansing as burdensome. Feasible, accurate and well accepted non-invasive diagnostic techniques are needed for the determination of inflammatory activity and optimal tailoring of therapy. Hybrid PET/MRI represents an innovative combination of two established, non-invasive diagnostic tools: Magnetic resonance imaging (MRI), allowing for anatomic-functional imaging of the abdomen at high soft tissue contrast and positron emission tomography (PET) utilizing 18F-fluorodeoxyglucose (FDG) a non-invasive tool to monitor glucose metabolism and allowing a detection and quantification of inflammatory processes. Since MRI has limited sensitivity in UC and may be hampered by retained stool, a combination with another imaging modality is very appealing. PET, on the other side provides functional information, yet with limited anatomical landmarks and is relatively unsusceptible to artifacts associated to retained stool. In combination, these modalities might provide a valid alternative for the non-invasive assessment of the inflammatory activity in UC patients without the need for bowel purgation. It will therefore have to be investigated whether fecal material does impede the diagnostic quality of the combination of FDG-PET and MRI. For this purpose, the investigators will include 50 patients with confirmed ulcerative colitis. Dependent on clinical activity of the inflammation, patients will be randomized to undergo PET/MRI enterography either with or without prior bowel purgation followed by a colonoscopy. Inflammatory activity in 7 bowel segments will be analyzed based on PET/MRI with and without bowel purgation with the results of colonoscopy as standard of reference.
Patient acceptance of PET/MRI with and without bowel purgation as well as colonoscopy will be compared. PET/MRI with and without bowel cleansing will be compared with regard to diagnostic accuracy as well as for its patients' acceptance in comparison to colonoscopy.
The investigators hypothesize that PET/MRI will eventually be highly accurate to detect and monitor inflammatory activity in patients with ulcerative colitis. Additional information about extra-intestinal findings might also change the therapeutic concept. PET/MRI might serve as a non-invasive diagnostic option in patients with UC to quantify inflammatory activity especially when bowel cleansing or colonoscopy is not applicable.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- patients with confirmed ulcerative colitis verified by the defining symptoms (rectal bleeding, diarrhea), endoscopy and histopathology
- clinically indicated colonoscopy and 18F-FDG PET as either initial assessment or follow- up examination
- patient age ≥ 18 years
Exclusion criteria
- Patients aged < 18years
- Patients with MRI contraindications, e.g. presence of cardiac pacemaker, implanted cardioverter-defibrillator, neurostimulation systems or with claustrophobia.
- acute renal failure, severe chronic renal failure (calculated glomerular filtration rate [GFR] < 30 ml/min)
- allergy to i.v. gadolinium based contrast agents
Treatment and study plan
Colonoscopy
Diagnostic TestPrimary outcomes
-
Diagnostic accuracy of PET/MRI with and without bowel purgation
Time frame: 24 hours
Overall segment-based diagnostic accuracy using ileocolonoscopy as reference standard will be calculated for PET/MRI with and without bowel purgation
Secondary outcomes
-
Sensitivity of PET/MRI with and without bowel purgation in percent
Time frame: 24 hours
Overall segment-based sensitivity using ileocolonoscopy as reference standard will be calculated for PET/MRI with and without bowel purgation
-
Specificity of PET/MRI with and without bowel purgation in percent
Time frame: 24 hours
Overall segment-based specificity using ileocolonoscopy as reference standard will be calculated for PET/MRI with and without bowel purgation
-
Negative predictive value of PET/MRI with and without bowel purgation in percent
Time frame: 24 hours
Overall segment-based negative predictive value using ileocolonoscopy as reference standard will be calculated for PET/MRI with and without bowel purgation
-
Positive predictive value of PET/MRI with and without bowel purgation in percent
Time frame: 24 hours
Overall segment-based positive predictive value using ileocolonoscopy as reference standard will be calculated for PET/MRI with and without bowel purgation
-
Optimized cut-offs
Time frame: 24 hours
Optimized cut-offs for PET for each bowel segment using ileocolonoscopy as reference standard for each colon segment will be calculated
-
Patient acceptance
Time frame: 24 hours
18F-FDG PET/MRI without bowel cleansing shows higher patient acceptance than conventional colonoscopy
-
Description of extraintestinal findings
Time frame: 24 hours
Extraintestinal findings will be assessed by evaluating PET/MRI images
-
The Boston Bowel Preparation Scale
Time frame: 24 hours
Bowel Preparation Quality will be assessed for both patient groups
Sponsors and collaborators
Lead sponsor
Universität Duisburg-Essen
Other
Collaborators
- Crohn's and Colitis Foundation
Registry information
Official study title
Positron Emission Tomography With 18F-fluorodeoxyglucose Combined With MRI for Monitoring Inflammatory Activity in Patients With Ulcerative Colitis
Important dates
- Study start
- 2016
- Primary completion
- 2018
- Study completion
- 2018
- First posted
- Dec 19, 2018
- Registry last updated
- Dec 19, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Medication Adherence in Patients With Inflammatory Bowel Disease (IBD)
NCT02620514
Colitis, Colitis, Ulcerative
Atlanta, Georgia, United States
View Trial DetailsStudy of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease
NCT03000101
Colitis, Colitis, Ulcerative
Bologna, Italy
View Trial DetailsGI Permeability Change in Response to Aquamin®
NCT04855799
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial DetailsIBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
NCT06094608
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial Details